Fovista AMD Failure Puts Eylea In The Clear, Blurs Anti-PDGF Prospects
The failure of two Phase III Fovista and Lucentis combination trials in treating wet AMD probably lifts the threat of shifts towards PDGF/VEGF combinations and thereby leaves Regeneron's Eylea sales in the clear.
You may also be interested in...
Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.
ON the lookout for potential ophthalmology options despite recent setbacks in the area, Novartis has now spotted ECF843, an investigative recombinant human lubricin – or natural lubricant – for dry eye.
Finance Watch: Surrozen Raises $33m In $483m February Flurry; Also, Are Reverse Mergers This Year's IPOs?
Surrozen raised $33m to fund drug development programs targeting Wnt ligands for various indications during a February VC financing flurry that occurred despite a drop in IPOs. Taking an alternative route to going public, some biopharma companies have completed reverse mergers in recent weeks and months.